Tae-You Kim: h-index, Total Citations, and Citation Map
Tae-You Kim's h-index is 10 (10 i10-index, 22,445+ total citations across 10+ publications) according to Google Scholar as of June 2026. Tae-You Kim is affiliated with Seoul National University.
Tae-You Kim is a researcher affiliated with Seoul National University, specializing in oncology. Their work has been cited 22,445 times. This profile visualizes their global influence, highlighting strong citation networks in China.
Tae-You Kim's Citation Metrics
Bibliometric impact based on 10 indexed publications.
- H-Index
- 10
- i10-Index
- 10
- Total Citations
- 22,445
- Citing Countries
- 3
As of June 2026.
Tae-You Kim has an h-index of 10 and 22,445 total citations across 10 publications, with research cited by institutions in 3 countries.
Download Exports (PNG, CSV, Poster)
Free Viewing Tae-You Kim's citation map is always free. Pay once to download poster, PNG, and CSV files for offline use or your visa packet.
We've mapped 5,000 of 22,445 citations for Tae-You Kim
We've shown the most-cited 5,000. Unlock the full crawl (22,395 more citations) to see every institution citing this scholar.
Global Impact Map
Visualizing the geographic distribution of institutions that have cited your work.
Starting…
Pins will appear here as institutions are resolved — no need to refresh.
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
20208,170
Top Citing Countries
Top Citing Institutions
Visa Evidence Package
Views and exports tuned for EB-1A, O-1A, and EB-2 NIW petitions. Sustained acclaim, geographic reach, and independent-citation filtering are the strongest evidence categories immigration adjudicators look for.
Citation trend (last 10 years)Click to expand
Citation Trend (Last 10 Years)
Related Guides
Learn how to use citation maps for your research and visa applications.
About Tae-You Kim's research
Tae-You Kim is a researcher in oncology at Seoul National University. Their work has been cited 22,445 times across 10 publications (h-index 10), according to Google Scholar.
Their most-cited work, “Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma” (2020), has accumulated 8,170 citations. Other influential works include “Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial” (2017) with 4,850 citations and “Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a …” (2014) with 2,954 citations.
Citations of Tae-You Kim's research come primarily from China, Netherlands and United States, reflecting international research impact. The interactive citation map above shows the full geographic distribution of the institutions citing this work.
